Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03605966 · ClinicalTrials.gov registry record
Developing a Method to Objectively Measure Opioid Analgesia
A clinical trial of Analgesics, Antipyretics and Anti-Inflammatory Drugs Causing Adverse Effects in Therapeutic Use, sponsored by Julia Finkel.
- Active
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT03605966: Active study of Analgesics, Antipyretics and Anti-Inflammatory Drugs Causing Adverse Effects in Therapeutic Use, sponsored by Julia Finkel.
NCT03605966 is a study of Analgesics, Antipyretics and Anti-Inflammatory Drugs Causing Adverse Effects in Therapeutic Use that is active but no longer recruiting, run by Julia Finkel. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03605966, a study of Analgesics, Antipyretics and Anti-Inflammatory Drugs Causing Adverse Effects in Therapeutic Use, is active but no longer recruiting, sponsored by Julia Finkel.
- ACTIVE NOT RECRUITING
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Inappropriate prescribing is the fundamental upstream driver of the opioid epidemic. Objective measures to determine the appropriateness of an opioid intervention, provide monitoring of the therapy for adequacy of dose and detection of tolerance or hyperalgesia would eliminate the subjective nature of opioid mediated pain management and obviate iatrogenic facilitation of opioid abuse. The present study is designed to objectively determine whether our device can pain type and determine analgesic efficacy thereby optimizing treatment selection and opioid management.
Primary Outcome
The primary measurable outcomes for this study are the changes in the PRD area under the curve (AUC) that occur as a response to an opioid exposure. The differences are calculated by comparing the parameters from before the opioid dose to various time points after the opioid dose.
Conditions Studied
Study Locations (1)
District of Columbia
- Children's National Health System - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-07-01 |
| Est. Completion | 2025-12-01 |
What the registry record for NCT03605966 still lists
NCT03605966 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.
The record links to 1 condition, with Analgesics, Antipyretics and Anti-Inflammatory Drugs Causing Adverse Effects in Therapeutic Use appearing as the primary indexed condition, and to 0 interventions.
NCT03605966 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT03605966 about?
NCT03605966 is a clinical study titled "Developing a Method to Objectively Measure Opioid Analgesia". Inappropriate prescribing is the fundamental upstream driver of the opioid epidemic. Objective measures to determine the appropriateness of an opioid intervention, provide monitoring of the therapy for adequacy of dose and detection of tolerance or hyperalgesia would eliminate the subjective nature ...
What is the current status of trial NCT03605966?
This trial is currently active not recruiting. The enrollment target is 40 participants. The study started on 2018-07-01. Estimated completion is 2025-12-01.
What conditions does trial NCT03605966 study?
This clinical trial studies the following conditions: Analgesics, Antipyretics and Anti-Inflammatory Drugs Causing Adverse Effects in Therapeutic Use.
Who is sponsoring clinical trial NCT03605966?
This trial is sponsored by Julia Finkel, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03605966 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI